Core Viewpoint - HeYue-B (02256) has seen a significant stock price increase of nearly 40% post-earnings, reaching a historical high of 14.65 HKD, driven by strong financial performance and positive market sentiment [1] Financial Performance - For the first half of the year, the company reported revenue of 612 million HKD, representing a year-on-year growth of 23% [1] - The profit for the same period was 328 million HKD, showing a substantial year-on-year increase of 59% [1] Key Drivers - The earnings exceeded expectations primarily due to Merck's exercise of the commercialization option for pimicotinib, which resulted in a one-time fee of 85 million USD received in May [1] - The company announced that Merck exercised its global commercialization option for pimicotinib in April [1] Market Outlook - Citigroup has indicated that the current valuation of HeYue is low, considering the high certainty of its two late-stage candidates, pimicotinib and irpagratinib, along with a differentiated innovation pipeline that may lead to external licensing opportunities [1] - The firm anticipates significant catalysts for the company in 2025 and 2026, focusing on the approval and commercialization of pimicotinib, the release of phase III data for irpagratinib, and updates on other candidates like ABSK043 and ABSK061 [1]
港股异动 和誉-B(02256)涨近9%再创新高 匹米替尼行权费提振业绩 公司上半年纯利同比增长59%